MS specialists share evidence-based answers on issues from ranging from contraception and conception to breastfeeding, with particular attention to the safety of various disease-modifying therapies.
A noninferiority trial finds only a small difference in MRI activity in patients 55 or older who stopped DMT after five years of disease stability.
A major randomized trial comparing escalation of disease-modifying therapy versus early highly effective treatment is being extended from three to six years with an enhanced focus on clinical endpoints.
For young patients on platform injectable disease-modifying therapy (DMT), switching to an oral or infusion DMT was associated with lower relapse rates compared with switching to another injectable DMT.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Observational studies have much to add to clinical decision-making in MS care. Our latest podcast features insights from a leader in harnessing real-world data to guide individualized MS therapy.
Treatment with an anti-CD20 drug or fingolimod raised risk of breakthrough infection in vaccinated patients, but outcomes remained good.
Stopping or delaying disease-modifying therapy doesn’t appear to lower susceptibility to COVID-19 or the risk of complications from it. But data to date are not definitive, and decisions should be individualized.
Disease-modifying therapy for multiple sclerosis is not without risks. Since its benefits may wane as immune function diminishes with age, discontinuation is tempting. A new study gives supportive reassurance.
The 2018 guideline update includes 30 recommendations — 17 on initiating DMT treatment, 10 on switching DMT agents and three on stopping DMT. The lead author shares key takeaways.